잠시만 기다려 주세요. 로딩중입니다.

Combined Treatment with Anticancer Vaccine Using Genetically Modified Endothelial Cells and Imatinib in Bladder Cancer

대한비뇨기과학회지 2011년 52권 5호 p.327 ~ 334
하승범 ( Ha Seung-Beom ) - Seoul National University College of Medicine Department of Urology

박용현 ( Park Yong-Hyun ) - Seoul National University College of Medicine Department of Urology
이은혜 ( Lee Eun-Hye ) - Seoul National University College of Medicine Department of Urology
구자현 ( Ku Ja-Hyeon ) - Seoul National University College of Medicine Department of Urology
김현회 ( Kim Hyeon-Hoe ) - Seoul National University College of Medicine Department of Urology
곽철 ( Kwak Cheol ) - Seoul National University College of Medicine Department of Urology

Abstract


Purpose: We sought to maximize the antitumor effect of an anticancer vaccine based on genetically modified endothelial cells by combining it with the platelet-derived growth factor receptor inhibitor imatinib.

Materials and Methods: Human umbilical vein endothelial cells (HUVECs) were infected with 10 MOI of Ad-CMV-mGMCSF to make anticancer vaccines. One million mouse bladder cancer cells (MBT-2) were subcutaneously inoculated in C3H mice. The experimental groups included the following: Group 1 (phosphate-buffered saline), Group 2 (anticancer vaccine and GM-CSF), Group 3 (imatinib), and Group 4 (anticancer vaccine, GM-CSF, and imatinib). Tumor growth and body weight were measured weekly. At 4 weeks, the tumors were immunostained with anti-CD31, and microvessel density (MVD) was measured. To evaluate the immunological mechanism of each treatment, flow cytometry analysis of activated CD4 and CD8 cells was performed.

Results: At 4 weeks, the mean body weight of each group, excluding the extracted tumor weight, was not significantly different. Since week 3, the mean tumor volume in Group 4 was the smallest among the treatment groups (p<0.05), and a synergistic suppressive effect on tumor volume was observed in Group 4. The MVD in Group 4 was the most suppressed among the treatment groups (p<0.05), and a synergistic anti-angiogenic effect was observed. Flow cytometry analysis revealed that activated CD4+ and CD8+ cells increased in Group 2 and decreased in Group 3 compared with the other groups.

Conslusions: The combination of genetically modified endothelial cell vaccines and imatinib showed a synergistic antiangiogenic effect in bladder cancer.

키워드

Immunotherapy; Platelet-derived growth factor; Urinary bladder neoplasms
원문 및 링크아웃 정보
   
등재저널 정보
KCI
KoreaMed
KAMS